Worlds first implantable ceramic sternum developed by I.CERAM and Dr. François Bertin
The CHU Limoges and I.CERAM, a specialist in ceramic implants, is proud to announce the successful implant of the worlds’s first porous alumina ceramic sternum. This ground breaking and innovative operation was performed on a cancer patient by Dr. François Bertin at the Limoges University Hospital on the 19th of March 2015.
A major therapeutic advance:
This marks a turning point in surgery infections and bone metastases by virtually eliminating the risk of infection to the patient through sustainable bone integration of the implant and a significant reduction in operation time. This surgery uses a technology 100% biocompatible and rehabitable: a complete porous alumina ceramic sternum.
Currently, the “traditional” treatments used to date in the case of an infected sternum or metastases are complex, long, limited (titanium or part bone cement with metal fasteners) and increasingly puts the patient at risk of infection.
Besides the purity factors related to the characteristics of alumina (Al2O3), the CERAMIL sternum is completely inert and provides total biocompatibility associated with an improved mechanical resistance. Its porosity, identical to that of human bone, promotes the movement of cells, becoming an integral part of the bone implant in the course of 6 months. This durable bone integration significantly improves the comfort and the quality of life of patients due to the increased flexibility of the chest after the operation.
After three months of clinical trials, the operation is a success. “The results of the operation is very positive and the patient is improving. The I.CERAM ceramic sternum has fully met my expectations during the operation. From a surgical point of view, this is an important development for a significant time saving procedure. Moreover biocompatibility combined with the strength of the material allows us to return to the essence of surgery by providing a more natural operation, limiting the risk of infection and rejection. “Said Dr. François Bertin, who helped design the device and put the implant.
This success demonstrates the expertise of I.CERAM that has over 10 years experience in the field of porous ceramic as well as its ability to manufacture large size implants in this material.
Accelerating the development of “bone implant active molecules” of I.CERAM
This is a major step in the deployment of the “bone implant active molecules” of I.CERAM, revolutionising the treatment of bone infections.
“We are proud of the success of this collaboration between the teams of I.CERAM and the Limoges University Hospital that took place over a period of more than 18 months. Our porous alumina sternum provides a unique solution in the treatment of infected sternums, to date no satisfactory treatment is available. “We will accelerate our R & D in order to assure that in 18 months time, a sternum loaded with active molecules can provide treatment for bone infections“, says André Kérisit, president of I.CERAM.
This innovation is part of a pilot study at the front of a multi centred clinical study. With nearly 2% to 4% of prostheses infected annually worldwide, I.CERAM opens the door to a major market: that being the treatment of bone infections.
With this world first, I.CERAM validates and reaffirms its determination to become a major player in the field of bioceramic implants for all types of bone infections.